A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-Naïve HIV-Infected Patients: SPARTAN Study Results

J. Kozal, Michael; Lupo, Sergio; DeJesus, Edwin; Molina, Jean‐Michel; McDonald, Cheryl; Raffi, François; Benetucci, Jorge; Mancini, Marco; Yang, Rong; Wirtz, Victoria; Percival, Lisa; Zhang, Jenny; Zhu, Li; Arikan, Dilek; Farajallah, Awny; Nguyen, Bach‐Yen; Y. Leavitt, Randi; McGrath, Donnie; Lataillade, Max; the SPARTAN Study Team, for

doi:10.1310/hct1303-119

Public

A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-Naïve HIV-Infected Patients: SPARTAN Study Results

Published in HIV Clinical Trials • Jun 1, 2012

Authors:

Michael J. Kozal

Sergio Lupo

Edwin DeJesus

Abstract

BACKGROUND: Nucleoside and ritonavir (RTV) toxicities have led to increased interest in nucleoside reverse transcriptase inhibitors (NRTIs) and RTV-sparing antiretroviral regimens. SPARTAN was a multicenter, randomized, open-label, noncomparative pilot study evaluating the efficacy, safety, and resi...

Subject

Raltegravir

Medicine

Ritonavir

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!